Patients prescribed extended anticoagulation for VTE have a lower risk of recurrent VTE with NOACs compared to warfarin, according to a study in JAMA Network…
Australian study shows AF patients on NOACs are less likely to experience cognitive decline than those on warfarin.
The combination of drugs is common and there is a dose-response relationship, researchers say.
New results from the VOYAGER PAD trial shows a benefit with no increase in bleeds.
Patients are missing out on timely review of their stroke risk in primary care, a study suggests.
The analysis in people with AF suggests a NOAC might be the better option for those at risk of osteoarthritis, authors say.
Emerging evidence suggests patients with AF who have a bleed should probably be investigated for malignancy, cardiologists warn.
A secondary trial analysis shows low-dose rivaroxaban and aspirin benefit high-risk patients with lower extremity PAD, authors say.
Choosing between the two drugs is a choice between thrombotic or haemorrhagic risk.
Patients on NOACs pre-stroke do not appear to be at increased risk, say researchers.